These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15850563)

  • 1. Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete.
    Takahashi A; Inokoshi J; Chiba H; Omura S; Tanaka H
    Arch Biochem Biophys; 2005 May; 437(2):233-40. PubMed ID: 15850563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
    Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
    Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actinohivin: specific amino acid residues essential for anti-HIV activity.
    Takahashi A; Inokoshi J; Tsunoda M; Suzuki K; Takenaka A; Sekiguchi T; Omura S; Tanaka H
    J Antibiot (Tokyo); 2010 Nov; 63(11):661-5. PubMed ID: 20842142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity.
    Takahashi A; Inokoshi J; Hachiya A; Oka S; Omura S; Tanaka H
    J Antibiot (Tokyo); 2011 Aug; 64(8):551-7. PubMed ID: 21694730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities.
    Chiba H; Inokoshi J; Okamoto M; Asanuma S; Matsuzaki Ki ; Iwama M; Mizumoto K; Tanaka H; Oheda M; Fujita K; Nakashima H; Shinose M; Takahashi Y; Omura S
    Biochem Biophys Res Commun; 2001 Mar; 282(2):595-601. PubMed ID: 11401502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular cloning of actinohivin, a novel anti-HIV protein from an actinomycete, and its expression in Escherichia coli.
    Inokoshi J; Chiba H; Asanuma S; Takahashi A; Omura S; Tanaka H
    Biochem Biophys Res Commun; 2001 Mar; 281(5):1261-5. PubMed ID: 11243871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
    Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
    Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel heme-containing protein with anti-HIV-1 activity from skin secretions of Bufo andrewsi.
    Zhao Y; Jin Y; Wang JH; Wang RR; Yang LM; Lee WH; Zheng YT; Zhang Y
    Toxicon; 2005 Nov; 46(6):619-24. PubMed ID: 16157359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120.
    Zhang F; Hoque MM; Jiang J; Suzuki K; Tsunoda M; Takeda Y; Ito Y; Kawai G; Tanaka H; Takénaka A
    Chembiochem; 2014 Dec; 15(18):2766-73. PubMed ID: 25403811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
    Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
    Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated polymannuronate (SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities.
    Liu H; Geng M; Xin X; Li F; Zhang Z; Li J; Ding J
    Glycobiology; 2005 May; 15(5):501-10. PubMed ID: 15616125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium.
    Bokesch HR; O'Keefe BR; McKee TC; Pannell LK; Patterson GM; Gardella RS; Sowder RC; Turpin J; Watson K; Buckheit RW; Boyd MR
    Biochemistry; 2003 Mar; 42(9):2578-84. PubMed ID: 12614152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the specific anti-HIV property of actinohivin: structure of its complex with the α(1-2)mannobiose moiety of gp120.
    Hoque MM; Suzuki K; Tsunoda M; Jiang J; Zhang F; Takahashi A; Ohbayashi N; Zhang X; Tanaka H; Omura S; Takénaka A
    Acta Crystallogr D Biol Crystallogr; 2012 Dec; 68(Pt 12):1671-9. PubMed ID: 23151632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolic acid inhibits syncytium formation accompanied by reduction of gp120 expression.
    Ui H; Asanuma S; Chiba H; Takahashi A; Yamaguchi Y; Masuma R; Omura S; Tanaka H
    J Antibiot (Tokyo); 2005 Aug; 58(8):514-8. PubMed ID: 16266123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine.
    Hout DR; Gomez LM; Pacyniak E; Miller JM; Hill MS; Stephens EB
    Virology; 2006 May; 348(2):449-61. PubMed ID: 16458946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
    Li H; Song H; Heredia A; Le N; Redfield R; Lewis GK; Wang LX
    Bioconjug Chem; 2004; 15(4):783-9. PubMed ID: 15264865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
    Colleluori DM; Tien D; Kang F; Pagliei T; Kuss R; McCormick T; Watson K; McFadden K; Chaiken I; Buckheit RW; Romano JW
    Protein Expr Purif; 2005 Feb; 39(2):229-36. PubMed ID: 15642474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library.
    Han Z; Xiong C; Mori T; Boyd MR
    Biochem Biophys Res Commun; 2002 Apr; 292(4):1036-43. PubMed ID: 11944919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterobiaryl human immunodeficiency virus entry inhibitors.
    Lu RJ; Tucker JA; Pickens J; Ma YA; Zinevitch T; Kirichenko O; Konoplev V; Kuznetsova S; Sviridov S; Brahmachary E; Khasanov A; Mikel C; Yang Y; Liu C; Wang J; Freel S; Fisher S; Sullivan A; Zhou J; Stanfield-Oakley S; Baker B; Sailstad J; Greenberg M; Bolognesi D; Bray B; Koszalka B; Jeffs P; Jeffries C; Chucholowski A; Sexton C
    J Med Chem; 2009 Jul; 52(14):4481-7. PubMed ID: 19534463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.